As previously reported, Barclays upgraded Bayer (BAYRY) to Overweight from Equal Weight with a EUR 45 price target as the firm transferred coverage of European mid-cap pharma to a new analyst. The firm cites near-term potential it sees for the company to resolve its litigation overhang, as well as upside to kerendia forecasts and margin upside in the Crop Science segment.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer upgraded to Overweight from Equal Weight at Barclays
- Bayer added to European Conviction List at Goldman Sachs
- Bayer Tests Talcid in Real-World Acid Rebound Study: What It Means for BAYRY Investors
- Bayer Backs AskBio Gene Therapy Push in Pompe Disease: Early Trial Update and Investor Takeaways
- Bayer price target raised to EUR 41 from EUR 30.40 at Berenberg